Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

Guggenheim reaffirmed a buy rating on Pfizer with a $36 price target, about 38% above the recent ~$26 share price. The note highlighted Pfizer’s 96-drug pipeline, including 31 late-stage phase 3 assets, and pointed to upcoming mevrometostat phase 3 data expected in 2H 2026 as a potential catalyst. The stock also offers a recent 6.7% dividend yield, but Wall Street consensus remains cautious overall with 15 hold ratings versus 9 buys and 3 sells.

Analysis

PFE is screening like a classic late-cycle pharma value trap, but the market is likely underpricing the asymmetry embedded in its pipeline optionality. The key second-order effect is that a modest de-risking of one or two late-stage assets can matter more to equity value than near-term dividend yield optics, because the stock is trading as if patent erosion is a deterministic glide path rather than a series of binary events. That makes the name less about near-term earnings quality and more about the dispersion of outcomes over the next 12-24 months.

The more interesting angle is competitive positioning in obesity and oncology: Pfizer does not need to win category leadership to re-rate, it only needs to secure a credible “good enough” entrant in one of those markets to slow multiple compression. If its GLP-1 push gains traction, the real losers are not just direct obesity peers but also smaller biotechs and contract-development names that could see capital diverted toward larger, better-funded incumbents. Conversely, a clean failure in one marquee program would likely hit sentiment disproportionately because the stock is being supported by carry investors who are implicitly financing the pipeline wait with the dividend.

Consensus appears to be missing that the dividend is both support and trap. At these levels, yield buyers can dampen downside in the short run, but if the pipeline disappoints, the payout becomes a signal of stagnation rather than safety and the multiple can compress quickly. The market is probably underestimating the duration risk: the biggest catalysts are measured in quarters and years, not weeks, so this is a name where optionality exists but patience can be expensive if clinical momentum stalls.

Key Decisions for Investors

• Maintain a tactical long PFE only as a catalyst trade, not a core hold: initiate on weakness into the next clinical-data window and target a 10-15% move on positive readthrough; cut exposure if pipeline news flow turns negative before late-2026.
• Sell covered calls against existing PFE longs 3-6 months out to monetize the dividend/carry while capping upside; attractive if you view the stock as range-bound pending data.
• Pair trade: long PFE / short a basket of higher-multiple obesity and single-asset biotech exposure to express relative pipeline optionality with lower valuation risk; monitor for GLP-1 readouts as the main catalyst.
• If looking for a lower-risk income trade, prefer PFE only versus other ex-growth pharma with weaker balance sheets; the dividend provides a floor, but size positions for clinical binary risk, not yield.
• Avoid chasing the stock ahead of late-stage data in 2H26; the better risk/reward is likely post-event, where a negative outcome may create a temporary dislocation that the dividend can help underwrite.